Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome

International Journal of Pediatric Endocrinology

Erica A Eugster²  Charles Sultan³  Françoise Paris³  Franco Guzman¹  Sally Garnett⁴  Emily K Sims² 

[1] Former-AstraZeneca, Wilmington, Delaware, USA;Section of Pediatric Endocrinology/Diabetology, Riley Hospital for Children, Indiana University School of Medicine, 705 Riley Hospital Drive, Room 5960, Indianapolis, IN 46202, USA;Pediatric Gynecology and Endocrinology, University Hospital of Montpellier, Montpellier, France;AstraZeneca, Macclesfield, United Kingdom

关键词: Estrogen receptor antagonist;    Peripheral precocious puberty;    McCune Albright syndrome;   

Others  :  813451
DOI  :  10.1186/1687-9856-2012-26

 received in 2012-06-20, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

McCune-Albright Syndrome (MAS) is usually characterized by the triad of precocious puberty (PP), fibrous dysplasia, and café au lait spots. Previous treatments investigated for PP have included aromatase inhibitors and the estrogen receptor modulator, tamoxifen. Although some agents have been partially effective, the optimal pharmacologic treatment of PP in girls with MAS has not been identified. The objective of this study was to evaluate the safety and efficacy of fulvestrant (Faslodex^TM), a pure estrogen receptor antagonist, in girls with progressive precocious puberty (PP) associated with McCune-Albright Syndrome (MAS).

Methods

In this prospective international multicenter trial, thirty girls ≤ 10 years old with MAS and progressivePP received fulvestrant 4 mg/kg via monthly intramuscular injections for 12 months. Changes in vaginal bleeding, rates of bone age advancement, growth velocity, Tanner staging, predicted adult heights, and uterine and ovarian volumes were measured.

Results

Median vaginal bleeding days decreased from 12.0 days per year to 1.0 day per year, with a median change in frequency of -3.6 days, (95% confidence interval (CI) -10.10, 0.00; p = 0.0146). Of patients with baseline bleeding, 74% experienced a ≥50% reduction in bleeding, and 35% experienced complete cessation during the study period (95% CI 51.6%, 89.8%; 16.4%, 57.3%, respectively). Average rates of bone age advancement (ΔBA/ΔCA) decreased from 1.99 pre-treatment to 1.06 on treatment (mean change -0.93, 95% CI -1.43, -0.43; p = 0.0007). No significant changes in uterine volumes or other endpoints or serious adverse events occurred.

Conclusions

Fulvestrant was well tolerated and moderately effective in decreasing vaginal bleeding and rates of skeletal maturation in girls with MAS. Longer-term studies aimed at further defining potential benefits and risks of this novel therapeutic approach in girls with MAS are needed.

Trial registration

NCT00278915

【 授权许可】

   
2012 Sims et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]McCune D: Osteitis fibrosa cystica; the case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 1936, 52:743-744.
• [2]Albright F, Butler AM, Hampton AO, Smith P: Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females: report of five cases. N Engl J Med 1937, 216:727-776.
• [3]Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM: Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991, 325(24):1688-1695.
• [4]Happle R: The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 1986, 29(4):321-324.
• [5]Haddad N, Eugster E: An update on the treatment of precocious puberty in McCune-Albright syndrome and testotoxicosis. J Pediatr Endocrinol Metab 2007, 20(6):653-661.
• [6]Foster CM, Feuillan P, Padmanabhan V, Pescovitz OH, Beitins IZ, Comite F, Shawker TH, Loriaux DL, Cutler GB Jr: Ovarian function in girls with McCune-Albright syndrome. Pediatr Res 1986, 20(9):859-863.
• [7]Kaufman FR, Costin G, Reid BS: Autonomous ovarian hyperfunction followed by gonadotrophin-dependent puberty in McCune-Albright syndrome. Clin Endocrinol (Oxf) 1986, 24(3):239-242.
• [8]Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer 2000, 89(4):817-825.
• [9]Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH: Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003, 143(1):60-66.
• [10]Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, et al.: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20(16):3386-3395.
• [11]Rao S, Colaco MP, Desai MP: McCune Albright Syndrome (MCAS): a case series. Indian Pediatr 2003, 40(1):29-35.
• [12]Sorgo W, Kiraly E, Homoki J, Heinze E, Teller WM, Bierich JR, Moeller H, Ranke MB, Butenandt O, Knorr D: The effects of cyproterone acetate on statural growth in children with precocious puberty. Acta Endocrinol (Copenh) 1987, 115(1):44-56.
• [13]Syed FA, Chalew SA: Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report. J Pediatr Endocrinol Metab 1999, 12(1):81-83.
• [14]Janssen PA, Symoens JE: Hepatic reactions during ketoconazole treatment. Am J Med 1983, 74(1B):80-85.
• [15]Sarver RG, Dalkin BL, Ahmann FR: Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. Urology 1997, 49(5):781-785.
• [16]Shulman DI, Francis GL, Palmert MR, Eugster EA: Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008, 121(4):e975-e983.
• [17]Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB Jr: Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986, 315(18):1115-1119.
• [18]Feuillan PP, Jones J, Cutler GB Jr: Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993, 77(3):647-651.
• [19]Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuillan PP: Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003, 88(12):5730-5733.
• [20]Mieszczak J, Lowe ES, Plourde P, Eugster EA: The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 2008, 93(7):2751-2754.
• [21]Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT: Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007, 92(6):2100-2106.
• [22]Treilleux T, Mignotte H, Clement-Chassagne C, Guastalla P, Bailly C: Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature. Eur J Surg Oncol 1999, 25(5):477-482.